Lymphokines, E.g., Interferons, Interlukins, Etc. Patents (Class 530/351)
-
Patent number: 8697046Abstract: Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space.Type: GrantFiled: August 14, 2009Date of Patent: April 15, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rong Li, Sheldon S. Miller, Arvydas Maminishkis
-
Patent number: 8697045Abstract: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.Type: GrantFiled: August 26, 2011Date of Patent: April 15, 2014Assignee: Merck Sharp & Dohme CorporationInventors: Seoju Lee, David C. Wylie, Susan Cannon-Carlson
-
Publication number: 20140099280Abstract: The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.Type: ApplicationFiled: February 24, 2012Publication date: April 10, 2014Applicant: Cenre National De La Recherche ScientifiqueInventors: Jean-Philippe Girard, Corinne Cayrol-Girard, Emma Lefraancais
-
Patent number: 8691953Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: December 20, 2011Date of Patent: April 8, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
-
Publication number: 20140093875Abstract: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: ApplicationFiled: December 2, 2013Publication date: April 3, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Pedro A. Reche-Gallardo, Vassili Soumelis, Yong-Jun Liu, Rene de Waal Malefyt, J. Fernando Bazan, Robert A. Kastelein
-
Publication number: 20140094588Abstract: The present invention relates to a method of predicting the course of disease in a patient having a malignant melanoma, the method comprising determining in melanoma cells comprised in a sample obtained from said malignant melanoma the presence or amount of at least five biomarkers selected from the group comprising or consisting of MTAP, PTEN, Bax, Bcl-X, ?-Catenin, CD20, Cox-2, CD49d and MLH1, wherein the absence or decreased amount of MTAP and ?-Catenin and/or the presence or increased amount of PTEN, Bax, Bcl-X, CD20, Cox-2, CD49d and MLH1, is associated with a disadvantageous course of disease.Type: ApplicationFiled: March 30, 2012Publication date: April 3, 2014Applicants: Universität RegensburgInventors: Stefanie Meyer, Anja Bosserhoff, Peter Wild, Thomas Fuchs
-
Patent number: 8685728Abstract: The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD).Type: GrantFiled: January 30, 2009Date of Patent: April 1, 2014Assignee: Rutgers The State University of New JerseyInventors: Yufang Shi, Guangwen Ren, Liying Zhang
-
Publication number: 20140086871Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.Type: ApplicationFiled: January 9, 2013Publication date: March 27, 2014Applicant: THE SCRIPPS RESEARCH INSTITUTEInventor: THE SCRIPPS RESEARCH INSTITUTE
-
Patent number: 8679494Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.Type: GrantFiled: April 22, 2009Date of Patent: March 25, 2014Assignee: UCB Pharma S.A.Inventors: Thomas Allen Ceska, Alistair James Henry
-
Publication number: 20140079701Abstract: The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.Type: ApplicationFiled: December 22, 2011Publication date: March 20, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Brian Robert Miller, Scott Glaser, Justin Caravella, Susan Foley, Xiaoping Hronoeski, Tigran Dikran Alvazian
-
Publication number: 20140079668Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).Type: ApplicationFiled: August 30, 2013Publication date: March 20, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: SHERIE L. MORRISON, TZU-HSUAN HUANG, CAIYUN XUAN
-
Publication number: 20140065175Abstract: The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology.Type: ApplicationFiled: February 17, 2012Publication date: March 6, 2014Inventors: M. Covadonga Alonso Martí, José Ángel Martínez Escribano
-
Publication number: 20140056843Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.Type: ApplicationFiled: May 24, 2013Publication date: February 27, 2014Applicant: APOGENIX GMBHInventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN
-
Publication number: 20140058790Abstract: Methods and compositions described herein relate to processes for the production of deuterated peptides, and the deuterated peptides produced accordingly. Deuterated peptides produced according to methods and compositions described herein may be produced more efficiently than such peptides produced according to prior art processes. The production process of according to methods and compositions described herein may lead to advantages in yield, purity, and/or price for deuterated peptides. Methods of marketing deuterated peptides are also disclosed.Type: ApplicationFiled: November 30, 2011Publication date: February 27, 2014Applicant: AmideBio LLCInventors: Michael H.B. Stowell, Mikhail Plam
-
Publication number: 20140050693Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.Type: ApplicationFiled: August 9, 2013Publication date: February 20, 2014Applicant: TECHNISCHE UNIVERSITAT MUNCHENInventors: Ame Skerra, Ina Theobald, Martin Schlapschy
-
Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection
Patent number: 8652457Abstract: The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals.Type: GrantFiled: July 13, 2012Date of Patent: February 18, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Jordan Marshall Sand, Mark Eric Cook -
Publication number: 20140044675Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.Type: ApplicationFiled: August 6, 2013Publication date: February 13, 2014Applicant: Roche Glycart AGInventors: Ralf Hosse, Christian Klein, Ekkehard Moessner, Laurence Bernard Peterson, Pablo Umana, Linda Wicker
-
Publication number: 20140044674Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.Type: ApplicationFiled: August 5, 2013Publication date: February 13, 2014Applicant: Roche Glycart AGInventors: Lydia Jasmin Duerner, Thomas Emrich, Jens Fischer, Ralf Hosse, Ekkehard Moessner, Pablo Umana, Daigen Xu
-
Publication number: 20140045242Abstract: The present invention concerns methods and compositions for forming anti-cancer vaccine complexes. In preferred embodiments, the anti-cancer vaccine complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the vaccine complex. The anti-cancer vaccine complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138negCD20+ MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.Type: ApplicationFiled: September 16, 2013Publication date: February 13, 2014Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20140045216Abstract: Polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) are disclosed. Also disclosed are fusion proteins comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide. Also disclosed are protein expression vectors comprising a promoter operably linked to a first DNA sequence encoding a signal sequence comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip) and a second DNA sequence encoding a heterologous polypeptide fused in frame to the first DNA sequence. Further disclosed are methods of producing a polypeptide comprising expressing a fusion protein comprising a polypeptide signal sequences of modified fragments of human immunoglobulin heavy chain binding protein (Bip) operably linked to a heterologous polypeptide and recovering the heterologous polypeptide.Type: ApplicationFiled: November 22, 2011Publication date: February 13, 2014Applicant: Callidus Biopharma, Inc.Inventor: Hung Do
-
Publication number: 20140046026Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.Type: ApplicationFiled: December 22, 2011Publication date: February 13, 2014Applicant: BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Kenan Christopher Garcia, Aron Levin, Aaron Ring
-
Patent number: 8647662Abstract: The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.Type: GrantFiled: November 13, 2012Date of Patent: February 11, 2014Assignee: Stemnion, Inc.Inventors: David L. Steed, Linda O. Palladino
-
Patent number: 8647663Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.Type: GrantFiled: November 14, 2012Date of Patent: February 11, 2014Assignee: Stemnion, Inc.Inventors: David L. Steed, Randall G. Rupp, Howard C. Wessel
-
Patent number: 8647866Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: GrantFiled: January 14, 2013Date of Patent: February 11, 2014Assignee: ZymoGenetics, Inc.Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
-
Publication number: 20140038886Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and/or treatment of liver diseases or disorders.Type: ApplicationFiled: February 10, 2012Publication date: February 6, 2014Applicant: RUPRECHT-KARIS-UNVERSITAT HEIDELBERGInventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn
-
Publication number: 20140039158Abstract: Methods of preparing polymer target conjugates which are substantially free of polymer attachment on the N-terminal of the targets are provided. Also provided are compositions comprising a plurality of polymer-polypeptide conjugates, said polymer-polypeptide conjugate comprising a polypeptide covalently attached to at least one polymer through an epsilon amino group of a Lysine or a Histidine found on the polypeptide and said conjugates containing less than 5% of the polymer-polypeptide conjugates having a polymer attached to the N-terminal of the polypeptide; and polymer target conjugates comprising a target moiety selected from the group consisting of polypeptides, proteins and the like having at least one polymer attached thereto at a site which is not the N-terminal of the target.Type: ApplicationFiled: July 25, 2013Publication date: February 6, 2014Applicant: Belrose Pharma, Inc.Inventor: Hong Zhao
-
Patent number: 8642737Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: GrantFiled: July 29, 2011Date of Patent: February 4, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Andreas Ivens, Peter Turecek, Oliver Zoechling
-
Publication number: 20140030273Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.Type: ApplicationFiled: February 1, 2012Publication date: January 30, 2014Applicant: GENMAB A/SInventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
-
Publication number: 20140030215Abstract: Pharmaceutical compositions including macrophage activating factor (MAF) and method of producing same, particularly to MAF compositions essentially devoid of glycosidase enzymes. The compositions of the present invention and pharmaceutical compositions including same are particularly suitable for intravenous administration.Type: ApplicationFiled: October 7, 2013Publication date: January 30, 2014Inventor: Nobuto Yamamoto
-
Publication number: 20140030213Abstract: The present invention relates to methods for purification of recombinant human granulocyte colony stimulating factor (rHu GCSF). The present invention particularly relates to methods for purification of rHu GCSF involving techniques such as aqueous two phase extraction and multimodal chromatographic purification to obtain highly purified rHu GCSF. The present invention also provides a pharmaceutical composition comprising the rHu GCSF, purified using the methods described herein.Type: ApplicationFiled: June 19, 2013Publication date: January 30, 2014Inventors: Darpan Gupta, Rahul Bhambure, Rohit Sharma, Anurag Singh Rathore
-
Publication number: 20140030220Abstract: A recombinant fusion interferon for animals. The recombinant fusion interferon comprises an animal interferon and a Fc region of an animal immunoglobulin G (IgG). The animal interferon and the Fc region of the animal immunoglobulin G can be further joined by a linker. A polynucleotide that encodes the recombinant fusion interferon for animals, a method for producing the recombinant fusion interferon, and the use of the recombinant fusion interferon.Type: ApplicationFiled: July 24, 2012Publication date: January 30, 2014Applicant: SBC Virbac Biotech Co., Ltd.Inventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
-
Publication number: 20140030222Abstract: The present invention relates to a recombinant fusion interferon for animals, a pharmaceutical composition thereof, and the use of the recombinant fusion interferon. The recombinant fusion interferon is represented by formula (I) or formula (II), (Porcine interferon)-(Linker)n-(Porcine immunoglobulin Fc fragment) ??(I) (Porcine immunoglobulin Fc fragment)-(Linker)n-(Porcine Interferon) ??(II) wherein n is 0 or a positive integer between 1 to 10, the recombinant fusion IFN specifically binds an antibody that specifically binds porcine interferon and an antibody that specifically binds porcine immunoglobulin Fc fragment.Type: ApplicationFiled: July 17, 2013Publication date: January 30, 2014Applicant: SBC Virbac Biotech Co., Ltd.Inventors: Tsun-Yung Kuo, Chung-Chin Wu, Han-Ting Chen
-
Patent number: 8637034Abstract: The preset invention relates to combination pharmaceutical composition comprising an activated-potentiated from of an antibody to gamma interferon, and an activated-potentiated form of an antibody to S-100 protein and method of treating multiple sclerosis and other neurodegenerative diseases, as well as the diseases and conditions associated with neuroinfections.Type: GrantFiled: July 15, 2011Date of Patent: January 28, 2014Inventor: Oleg Iliich Epshtein
-
Patent number: 8636997Abstract: Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.Type: GrantFiled: September 12, 2012Date of Patent: January 28, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Roland Martin, Henry McFarland, Bibiana Bielekova, Thomas Waldmann
-
Patent number: 8637019Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response.Type: GrantFiled: November 2, 2010Date of Patent: January 28, 2014Assignee: Merck Sharp & Dohme Corp.Inventor: Leonard G. Presta
-
Publication number: 20140023617Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.Type: ApplicationFiled: April 4, 2012Publication date: January 23, 2014Applicant: NEOVACSInventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
-
Publication number: 20140024806Abstract: Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed.Type: ApplicationFiled: April 3, 2013Publication date: January 23, 2014Applicant: Ohio UniversityInventors: Marcia J. Kieliszewski, Jianfeng Xu, John Kopchick, Shigeru Okada, Gary Meyer
-
Patent number: 8632774Abstract: A binding domain polypeptide and fusion proteins thereof that recognize an IL6/IL6 receptor complex, as well as compositions and methods of use thereof.Type: GrantFiled: July 2, 2009Date of Patent: January 21, 2014Assignee: Emergent Product Development Seattle, LLCInventors: Lynda Misher, Alan Keith Lofquist, Peter Robert Baum, Peter Armstrong Thompson
-
Publication number: 20140017713Abstract: Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.Type: ApplicationFiled: February 10, 2012Publication date: January 16, 2014Applicant: ATGEN CO. LTD.Inventors: Jae Myun Lee, Joo Chun Yoon, Sang Woo Park, Jong Sun Kim
-
Patent number: 8628777Abstract: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.Type: GrantFiled: June 30, 2009Date of Patent: January 14, 2014Assignee: Genentech, Inc.Inventors: Audrey Goddard, Guohua James Pan
-
Publication number: 20140010832Abstract: Embodiments of the invention are described, including materials and methods for making molecules and materials that have a specific binding domain of a PlGF2. Embodiments include, for instance, medicaments, biomaterials, biomolecules, molecular fusions, and vaccines.Type: ApplicationFiled: July 2, 2013Publication date: January 9, 2014Applicant: EPFL-TTOInventors: Jeffrey A. Hubbell, Mikael Martino, Priscilla S. Maithili Briquez
-
Publication number: 20140011276Abstract: A formulation and method for cultivating dendritic killer cells is disclosed in the present invention. The formulation comprises an effective amount of at least one cytokine and the abovementioned cytokine is IL-15. Furthermore, the method for cultivating dendritic killer cells at least comprises the following steps. A peripheral blood mononuclear cell population is obtained from human blood at first. Effective amounts of the cytokines in the formulation mentioned above are then added into the peripheral blood mononuclear cell population and the abovementioned peripheral blood mononuclear cell population is placed for a first appropriate period.Type: ApplicationFiled: June 14, 2013Publication date: January 9, 2014Inventor: Jan-Mou LEE
-
Publication number: 20140010811Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: June 27, 2013Publication date: January 9, 2014Applicant: University of Pittsburgh - Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Patent number: 8623348Abstract: Disclosed is an interferon-? (IFN-?) fused protein having IFN-? fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-?, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.Type: GrantFiled: March 27, 2009Date of Patent: January 7, 2014Assignee: JW Pharmaceutical CorporationInventors: Chan Kyu Lee, Seonyoung Yang, Eun Ju Kang, Kang Ryu, Hyun Soo Lee, Yong Soo Bae
-
Publication number: 20140004081Abstract: The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.Type: ApplicationFiled: March 15, 2012Publication date: January 2, 2014Applicant: THE UNIVERSITY OF BIRMINGHAMInventors: Mark Cobbold, David Millar
-
Publication number: 20140004079Abstract: Disclosed is a method of eliciting an immune response to an antigen present endogenously in a mammal. The method may comprise administering to the mammal a composition comprising at least one immunomodulator for inducing cell differentiation and or antigen-presenting function of antigen-presenting cell precursor. The antigen-presenting cell precursor may have taken up the antigen. Also disclosed are a composition for use in the method, an adjuvant comprising the composition, the use of the composition and the immunomodulator as described herein.Type: ApplicationFiled: June 21, 2013Publication date: January 2, 2014Applicant: Agency for Science, Technology and ResearchInventors: Adam Joseph GEHRING, Antonio Bertoletti, Florent Ginhoux
-
Publication number: 20140005361Abstract: Disclosed are Fc-interferon-beta (Fc-IFN-?) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-? fusion proteins include variants of the interferon-beta (IFN-?) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.Type: ApplicationFiled: August 26, 2013Publication date: January 2, 2014Applicant: MERCK PATENT GMBHInventors: Stephen D. Gillies, Nigel John Watkins, Matthew Paul Baker, Kin-Ming Lo, Steven C. Degon
-
Patent number: 8617531Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.Type: GrantFiled: December 14, 2007Date of Patent: December 31, 2013Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, Mary S. Rosendahl
-
Patent number: 8618256Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: May 13, 2011Date of Patent: December 31, 2013Assignee: Bolder BiotechnologyInventor: George N. Cox
-
Patent number: 8617532Abstract: This invention relates to use protein-polymer conjugates described in the specification to treat various diseases, including disease is idiopaic myelofibrsis, polycythaemia vera, and essential thromobocythaemia.Type: GrantFiled: December 9, 2010Date of Patent: December 31, 2013Assignee: PharmaEssentia Corp.Inventors: Ko-Chung Lin, Rudolf Widmann